Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026
Corvus Pharmaceuticals (NASDAQ: CRVS) will host a conference call and webcast on March 12, 2026 at 4:30 pm ET (1:30 pm PT) to provide a business update and report fourth quarter 2025 financial results.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Corvus Pharmaceuticals (NASDAQ: CRVS) will host a conference call and webcast on March 12, 2026 at 4:30 pm ET (1:30 pm PT) to provide a business update and report fourth quarter 2025 financial results. The event offers live dial-in, instant telephone access, and a webcast via investor relations. A replay will be available on Corvus' website for 90 days.
Details
News Market Reaction – CRVS
On Mar 6, the first trading day after this news, CRVS closed 1.65% below the previous close.
Data tracked by StockTitan Argus for the Mar 6 session.
Key Figures
- Cash & securities
- $65.7M
- As of Sept 30, 2025 (Q3 2025 earnings)
- R&D expense
- $8.5M
- Q3 2025 vs $5.2M year-ago
- Net loss
- $10.2M
- Q3 2025
- Cash balance
- $74.4M
- End of Q2 2025
- Warrant proceeds
- $35.7M
- Warrant exercises in Q2 2025
- Net income
- $15.2M
- Q1 2025 including warrant liability gain
- Cash position
- $44.2M
- As of March 31, 2025
- Runway guidance
- Into Q4 2026
- Runway disclosed in Q1–Q3 2025 earnings
Previous Earnings Reports
-
Q3 2025 financials and clinical milestones, with runway into Q4 2026.
-
Announcement of Nov 4, 2025 business update and Q3 2025 results call.
-
Q2 2025 results with positive soquelitinib data and stronger cash balance.
-
Scheduling of Aug 7, 2025 business update and Q2 2025 results call.
-
Q1 2025 results with favorable Phase 1 data and strengthened cash position.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
SOUTH SAN FRANCISCO, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on March 12, 2026 at 4:30 pm ET (1:30 pm PT) to provide a business update and report fourth quarter 2025 financial results.
The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this link for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus’ website for 90 days.
About Corvus Pharmaceuticals:
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of immune diseases and cancer. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Soquelitinib is being evaluated in a registration Phase 3 clinical trial for relapsed/refractory PTCL and in a Phase 1 clinical trial for the treatment of atopic dermatitis. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com and LinkedIn.
INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
+1-650-900-4522
llea@corvuspharma.com
MEDIA CONTACT:
Sheryl Seapy
Real Chemistry
+1-949-903-4750
sseapy@realchemistry.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.